Women's Health Diagnostic Testing Markets
Even though slightly more than half of the US population is female, medical research historically has neglected the health needs of women, other than reproductive issues. However, during the past two decades, there have been major changes in government and private support of women’s health research -- in policies, regulations, and the organization of research efforts. In a recent Institute of Medicine (IOM) report, the Washington DC-based institute found that women’s health research has contributed to significant progress over the past 20 years in lessening the burden of disease and reducing deaths from some conditions for women, while other conditions have seen only moderate change or even little or no change.
This Kalorama Information report, Women's Health Diagnostic Testing Markets provides insight into this key area of testing. The following tests are among those covered in this report.
This report analyzes the current and potential world markets for key diagnostic tests targeted at women’s health. This report generally forecasts future market growth for these tests to 2015. Market segments covered include the world and North American markets.
This report also reviews the nature and direction of research and trends, and gives insight into some issues facing the industry. The report profiles several key companies, including large companies that have made names for themselves in the field, as well as smaller firms with market niches. These companies are involved in developing and marketing over the counter (OTC), point of care (POC) in vitro diagnostic (IVD) tests and screening systems. Some of the companies profiled include
This Kalorama Information report, Women's Health Diagnostic Testing Markets provides insight into this key area of testing. The following tests are among those covered in this report.
- Pregnancy and Ovulation Tests
- Bone Density Testing
- Prenatal Screening
- Ultrasound
- Mammography
- Pap Smears
- Colposcopy
- HPV Testing
- Ovarian Cancer Tests
- UTI Testing
- Neonatal Jaundice Testing
- Auto Immune Disease Testing
- Cystic Fibrosis Testing
This report analyzes the current and potential world markets for key diagnostic tests targeted at women’s health. This report generally forecasts future market growth for these tests to 2015. Market segments covered include the world and North American markets.
This report also reviews the nature and direction of research and trends, and gives insight into some issues facing the industry. The report profiles several key companies, including large companies that have made names for themselves in the field, as well as smaller firms with market niches. These companies are involved in developing and marketing over the counter (OTC), point of care (POC) in vitro diagnostic (IVD) tests and screening systems. Some of the companies profiled include
- GE Healthcare
- Hologic
- Perkin Elmer
- Philips Healthcare
- Siemens Healthcare
- Somagen Diagnostics.
- CHAPTER ONE: EXECUTIVE SUMMARY
- 1.1 Women’s Health in Focus
- 1.2 Diagnostics Moving Forward
- 1.2.1 Advancing Female Health
- 1.2.2 Studying the Most Relevant Groups
- 1.2.3 Translating Research into Practice
- 1.3 Key Issues Involving Women’s Health
- 1.4 Market Picture
- 1.4.1 Overall Trends
- 1.4.2 Key Diagnostic Forecasts
- 1.4.3 Methodology
- CHAPTER TWO: INTRODUCTION
- 2.1 Perspective on Women’s Health
- 2.2 Key Differences between the Sexes
- 2.2.1 Autoimmune Disease
- 2.2.2 Cancer
- 2.2.3 Musculoskeletal Health
- 2.2.4 Birth Defects
- 2.2.5 Urinary Tract Infections
- 2.3 Key Leading Causes of Death in Females
- 2.4 Demographics
- 2.4.1 What Claims Women’s Lives
- 2.5 Key Trends and Issues in Women’s Diagnostics
- 2.5.1 Understanding the Molecular Basis of Disease
- 2.5.2 Managing Cancer Disease and Costs
- 2.5.3 Ultrasound and Mammography Use Grows
- CHAPTER THREE: PREGNANCY AND OVULATION
- 3.1 Perspective on Testing
- 3.1.1 Digital Testing
- 3.2 OTC Test Market Forecast
- 3.3 Church & Dwight Co. Inc.
- 3.4 Inverness Medical Innovations
- 3.5 Siemens Healthcare Diagnostics
- CHAPTER FOUR: BONE DENSITY TESTING
- 4.1 Alarming Rise of Osteoporosis
- 4.1.1 Bone Mineral Density
- 4.1.2 Refining Diagnosis
- 4.2 Bone Densitometer Market Forecast
- 4.3 GE Healthcare
- 4.4 Hologic
- 4.5 Osteometer MediTech
- CHAPTER FIVE: PRENATAL SCREENING
- 5.1 Perspective
- 5.1.1 Advances
- 5.2 Value of Informed Choice
- 5.3 The Impact of Prenatal Genetic Testing
- 5.4 DNA Assay Market Forecast
- 5.5 PerkinElmer
- 5.6 Quest Diagnostics
- 5.7 Sequenom
- CHAPTER SIX: ULTRASOUND
- 6.1 History and Perspective
- 6.1.1 Advances in Technology
- 6.2 Obstetrics and Gynecology
- 6.3 Breast Imaging
- 6.4 Market Forecasts
- 6.4.1 Ob/Gyn Market
- 6.4.2 Breast Imaging
- 6.5 Analogic
- 6.6 Philips Healthcare
- 6.7 Siemens Healthcare
- CHAPTER SEVEN: MAMMOGRAPHY
- 7.1 Perspective
- 7.1.1 Routine Screening
- 7.2 Transitioning to Digital
- 7.3 Computer-Aided Detection
- 7.4 Market Forecasts
- 7.4.1 Mammography Systems
- 7.4.2 CAD
- 7.5 Carestream Health
- 7.6 FujiFilm Medical Systems USA
- 7.7 GE Healthcare
- 7.8 Hologic
- CHAPTER EIGHT: PAP SMEARS
- 8.1 Testing for Cervical Cancer
- 8.1.1 Types of Screening
- 8.2 Cervical Cancer Shot
- 8.3 A Market Need
- 8.3.1 IVD Market Forecasts
- 8.4 Becton Dickinson
- 8.5 Hologic
- 8.6 Innogenetics NV
- CHAPTER NINE: COLPOSCOPY
- 9.1 Biopsy Procedure
- 9.1.1 Pap Smear Concerns
- 9.1.2 Routine Use
- 9.2 Markets for Colposcopy Systems
- 9.2.1 Primary and Secondary Screening
- 9.3 CooperSurgical 95 Corporate Dr. Trumbull, CT 06611
- 9.4 Guided Therapeutics
- 9.5 NeoDiagnostix
- CHAPTER TEN: HPV TESTING
- 10.1 HPV Defined
- 10.1.1 High Risk Types
- 10.1.2 Relationship to Cervical Cancer
- 10.2 Vaccine Issues
- 10.3 Strong Market Expected
- 10.3.1 IVD Market Forecasts
- 10.4 Abbott Diagnostics
- 10.5 Hologic
- 10.6 Qiagen Benelux BV
- CHAPTER ELEVEN: OVARIAN CANCER
- 11.1 Types of Ovarian Cancer
- 11.2 Different Diagnostic Techniques
- 11.3 Tumor Markers and Antigens
- 11.4 CA-125 Market Forecast
- 11.5 Abbott Diagnostics
- 11.6 Fujirebio Diagnostics
- CHAPTER TWELVE: URINARY TRACT INFECTIONS
- 12.1 Leading Cause of Morbidity and Death
- 12.1.1 Impact of Hospital Acquired Infections
- 12.1.2 Impact on Women
- 12.2 E. coli the Key Culprit
- 12.3 Market Forecasts Molecular Testing
- 12.4 Amerifit
- 12.5 Liofilchem
- 12.6 Rheonix
- 12.7 Somagen Diagnostics
- CHAPTER THIRTEEN: NEONATAL JAUNDICE
- 13.1 Issues Involving Bilirubin
- 13.2 Two Factors in Neonates
- 13.3 Risk Factors
- 13.4 Autism Link
- 13.5 Market Forecasts Bilirubin Testing
- 13.6 Instrumentation Laboratory
- 13.7 Nova Biomedical
- 13.8 Siemens Healthcare Diagnostics
- 13.9 Wako Diagnostics
- CHAPTER FOURTEEN: AUTOIMMUNE DISEASE
- 14.1 Genetic Factors
- 14.2 Low-Level Autoimmunity
- 14.3 Impact on Females
- 14.4 Types of Autoimmune Disease
- 14.5 IVD Market Forecasts
- 14.6 Bio-Rad Laboratories
- 14.7 Kronus
- 14.8 Phadia
- 14.9 XDx
- CHAPTER FIFTEEN: CYSTIC FIBROSIS
- 15.1 Affecting the Entire Body
- 15.2 Reduced Life Expectancy
- 15.3 Genetics
- 15.4 Chronic Infections
- 15.5 Market Forecast Genetic Testing
- 15.6 AutoGenomics
- 15.7 GenMark Diagnostics
- 15.8 Gen-Probe
- 15.9 Luminex
- 15.10 Sequenom